[1] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clinm,2016,66(2):115-132.
[2] MMurakami S, Ito H, Tsubokawa N, et al.Prognostic va-lue of the new IASLC/ATS/ERS classification of clinical stage IA lung adenocarcinoma[J]. Lung Cancer,2015,90(2):199-204.
[3] Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017[J]. CA Cancer J Clin,2017,67(1):7-30.
[4] National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening[J]. N Engl J Med,2011,365(5):395-409.
[5] Ru Zhao Y, Xie X, de Koning HJ, et al. NELSON lung cancer screening study[J]. Cancer Imaging,2011,11,S79-S84.
[6] International Early Lung Cancer Action Program Investigators, Henschke CI, Yankelevitz DF, et al. Survival of patients with stage I lung cancer detected on CT scree-ning[J]. N Engl J Med,2006,355(17):1763-1771.
[7] Gulati S, Mulshine JL.Lung cancer screening guidelines: common ground and differences[J]. Transl Lung Cancer Res,2014,3(3):131-138.
[8] Zhou Q, Fan Y, Wu N, et al.Demonstration program of population-based lung cancer screening in China: Rationale and study design[J]. Thorac Cancer,2014,5(3):197-203.
[9] Zhou QH, Fan YG, Bu H, et al.China national lung cancer screening guideline with low-dose computed tomography (2015 version)[J]. Thorac Cancer,2015,6(6):812-818.
[10] Zhou Q, Fan Y, Wang Y, et al.China National Lung Cancer Screening Guideline with Low-dose Computed ?Tomography (2018 version)[J]. Zhongguo Fei Ai Za Zhi,2018,21(2):67-75.
[11] Zheng R, Zeng H, Zuo T, et al.Lung cancer incidence and mortality in China, 2011[J]. Thorac Cancer,2016,7(1):94-99.
[12] He YT, Zhang YC, Shi GF, et al.Risk factors for pulmonary nodules in north China: A prospective cohort study[J]. Lung Cancer,2018,120:122-129.
[13] Tang W, Wu N, Huang Y, et al.Results of low-dose computed tomography (LDCT) screening for early lung cancer: prevalence in 4 690 asymptomatic participants[J]. Zhonghua Zhong Liu Za Zhi,2014,36(7):549-554.
[14] Yang W, Qian F, Teng J, et al.Community-based lung cancer screening with low-dose CT in China: Results of the baseline screening[J]. Lung Cancer,2018,117:20-26.
[15] Patz EF Jr, Pinsky P, Gatsonis C, et al.Overdiagnosis in low-dose computed tomography screening for lung cancer[J]. JAMA Intern Med,2014,174(2):269-274.
[16] Santarpia M, Liguori A, D'Aveni A, et al. Liquid biopsy for lung cancer early detection[J]. J Thorac Dis,2018, 10(Suppl 7):S882-S897.
[17] Ooki A, Maleki Z, Tsay JJ, et al.A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA[J]. Clin Cancer Res,2017,23(22):7141-7152.
[18] Ostrow KL, Hoque MO, Loyo M, et al.Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR[J]. Clin Cancer Res,2010,16(13):3463-3472.
[19] Sozzi G, Roz L, Conte D, et al.Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study[J]. Am J Respir Crit Care Med,2009,179(1):69-74.
[20] Ilie M, Hofman V, Long-Mira E, et al."Sentinel" circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease[J]. PLoS One,2014,9(10):e111597.
[21] Jin X, Chen Y, Chen H, et al.Evaluation of Tumor-Derived Exosomal miRNA as Potential Diagnostic Biomar-kers for Early-Stage Non-Small Cell Lung Cancer Using Next-Generation Sequencing[J]. Clin Cancer Res,2017,23(17):5311-5319.
[22] Best MG, Sol N, Kooi I, et al.RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics[J]. Cancer Cell,2015,28(5):666-676.
